Invesco Ltd. Cytokinetics Inc Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Cytokinetics Inc stock. As of the latest transaction made, Invesco Ltd. holds 157,249 shares of CYTK stock, worth $10.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

157,249

Previous 136,312 15.36%

Holding current value

$10.4 Million

Previous $4.5 Million 91.92%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$33.23 - $54.96 $695,736 - $1.15 Million	20,937 Added 15.36%	157,249 $8.64 Million
Q2 2025 Aug 13, 2025	SELL	$29.84 - $42.92 $10.9 Million - $15.7 Million	-365,570 Reduced 72.84%	136,312 $4.5 Million
Q1 2025 May 12, 2025	SELL	$40.19 - $51.12 $638,337 - $811,938	-15,883 Reduced 3.07%	501,882 $20.2 Million
Q4 2024 Feb 13, 2025	BUY	$46.36 - $58.62 $680,286 - $860,189	14,674 Added 2.92%	517,765 $24.4 Million
Q3 2024 Nov 12, 2024	BUY	$51.22 - $60.16 $394,035 - $462,810	7,693 Added 1.55%	503,091 $26.6 Million

Q2 2024 Aug 13, 2024	SELL	$47.86 - $75.05 $39.3 Million - $61.7 Million	-822,140 Reduced 62.4%	495,398 $26.8 Million
Q1 2024 May 14, 2024	BUY	$63.75 - $108.06 $4.75 Million - $8.06 Million	74,558 Added 6.0%	1,317,538 $92.4 Million
Q4 2023 Feb 12, 2024	BUY	$26.88 - $83.49 $1.59 Million - $4.93 Million	59,100 Added 4.99%	1,242,980 $104 Million
Q3 2023 Nov 13, 2023	SELL	$29.46 - $36.61 $9.41 Million - $11.7 Million	-319,376 Reduced 21.25%	1,183,880 $34.9 Million
Q2 2023 Aug 11, 2023	BUY	$32.62 - $40.75 $840,780 - $1.05 Million	25,775 Added 1.74%	1,503,256 $49 Million
Q1 2023 May 12, 2023	BUY	$33.36 - $45.71 $891,646 - $1.22 Million	26,728 Added 1.84%	1,477,481 $52 Million
Q4 2022 Feb 13, 2023	BUY	$35.77 - $51.11 $1.44 Million - $2.06 Million	40,264 Added 2.85%	1,450,753 $66.5 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $33.3 Million - $47 Million	862,890 Added 157.58%	1,410,489 $68.3 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $5.05 Million - $7.29 Million	148,950 Added 37.36%	547,599 $21.5 Million
Q1 2022 May 16, 2022	SELL	$29.74 - $46.0 $10.7 Million - $16.6 Million	-361,020 Reduced 47.52%	398,649 $14.7 Million
Q4 2021 Feb 14, 2022	BUY	$34.35 - $46.38 $11.4 Million - $15.4 Million	332,610 Added 77.88%	759,669 $34.6 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $97,576 - $188,099	5,263 Added 1.25%	427,059 $15.3 Million
Q2 2021 Aug 17, 2021	BUY	$19.79 - $26.99 $25,410 - $34,655	1,284 Added 0.31%	421,796 $8.35 Million
Q1 2021 May 17, 2021	SELL	$18.57 - $25.68 $418,122 - $578,210	-22,516 Reduced 5.08%	420,512 $9.78 Million
Q4 2020 Feb 16, 2021	BUY	$15.26 - $28.61 $187,987 - $352,446	12,319 Added 2.86%	443,028 $9.21 Million
Q3 2020 Nov 16, 2020	SELL	$20.58 - $28.96 $3.27 Million - $4.6 Million	-158,858 Reduced 26.94%	430,709 $9.33 Million
Q2 2020 Aug 14, 2020	BUY	$11.15 - $24.64 $2.82 Million - $6.22 Million	252,532 Added 74.93%	589,567 $13.9 Million
Q1 2020 May 15, 2020	SELL	$8.75 - $16.3 $109,663 - $204,287	-12,533 Reduced 3.59%	337,035 $3.97 Million
Q4 2019 Feb 14, 2020	SELL	$7.95 - $11.84 $454,247 - $676,513	-57,138 Reduced 14.05%	349,568 $3.71 Million
Q3 2019 Nov 14, 2019	BUY	$10.82 - $14.25 $608,754 - $801,733	56,262 Added 16.05%	406,706 $4.63 Million
Q2 2019 Aug 14, 2019	SELL	$7.95 - $11.25 $973,048 - $1.38 Million	-122,396 Reduced 25.89%	350,444 $3.94 Million
Q1 2019 May 15, 2019	SELL	$5.95 - $10.19 $481,485 - $824,595	-80,922 Reduced 14.61%	472,840 $3.83 Million
Q4 2018 Feb 14, 2019	BUY	$5.91 - $9.29 $3.27 Million - $5.14 Million	553,762 New	553,762 $3.5 Million

Others Institutions Holding CYTK

# of Institutions

446

Shares Held

129M

Call Options Held

5.25M

Put Options Held

1.18M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $6.25B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account